You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

20 search results for: IL-4

Airway Remodeling in Type 2 Asthma is Driven by <b>IL-4</b> and IL-13

expert video

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

24 min

Pulmonology

Dr. Reynold Panettieri discusses how IL-4 and IL-13 drive airway remodeling in type 2 asthma.

Can targeting <b>IL-4</b> and IL-13 have an effect on relieving the burden of atopic and non-atopic comorbidities in AD?

expert video

Can targeting IL-4 and IL-13 have an effect on relieving the burden of atopic and non-atopic comorbidities in AD?

5 min

Dermatology

Dr. Amy Paller discusses how targeting IL-4 and IL-13 can improve burden of AD.

What role does <b>IL-4</b> and IL-13 have in driving Type 2 inflammatory skin disease (AD, PN, CSU)?

expert video

What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin disease (AD, PN, CSU)?

5 min

Dermatology

Dr. Oscar Palomares explains that IL-4 and IL-13 are crucial cytokines in type 2 inflammation, playing both unique and overlapping roles, including T cell expansion and contributing to clinical symptoms in chronic diseases.

<b>IL-4</b> Contributes to Systemic Type 2 Inflammation in AD

expert video

IL-4 Contributes to Systemic Type 2 Inflammation in AD

4 min

Dermatology

In this highlight video from the ADVENT AD symposium held at EADV’s 2024 Annual Meeting in Amsterdam, Dr. Stephan Weidinger discusses how IL-4 contributes to systemic type 2 inflammation in AD via several mechanisms, including T cell differentiation, B cell activation and IgE generation, and T regulatory cell inhibition.

Normalizing Skin Barrier by Inhibiting <b>IL-4</b> & IL-13, or IL-13 Alone

expert video

Normalizing Skin Barrier by Inhibiting IL-4 & IL-13, or IL-13 Alone

5 min

Dermatology

Dr. Ramien explores how advanced systemic therapies may modify atopic dermatitis pathomechanisms including skin barrier dysfunction, and neuroimmune dysregulation

expert video

Barrier disruption in AD and the development of environmental and food allergies

5 min

Dermatology

Dr. Casale discusses the critical role of barrier disruption in atopic dermatitis

expert video

What Drives PN Disease? Exploring the Complexity of PN Pathophysiology

15 min

Dermatology

Dr. Brian Kim discusses the numerous contributors to PN pathophysiology, including type 2 inflammation, neuronal dysfunction, and dermal fibrosis, emphasizing the unique and overlapping roles of IL 31, IL-4 and IL-13 in its pathology.

Learn more about how dysregulated type 2 inflammation contributes to polymorphous lesions and dermal epidermal splitting in bullous pemphigoid

Infographic

Bullous Pemphigoid (BP) Pathophysiology Infographic

4 min

Dermatology

A static infographic detailing how autoimmunity and Type 2 inflammation play a critical role in the pathophysiology of Bullous Pemphigoid (BP).

Infographic

FeNO: A Biomarker of Type 2 Inflammation in Pediatric Asthma Patients

5 min

Pulmonology

Learn about the role of FeNO as a noninvasive test to identify type 2 inflammation in pediatric patients with asthma

Infographic

Type 2 Inflammation Underpins Pediatric Severe Asthma

5 min

Pulmonology

Learn about the role type 2 inflammation plays in the burden and pathophysiology of severe asthma in pediatric patients.

videoanimation

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis

5 min

Dermatology

Learn more about how chronic and systemic type 2 inflammation contributes to skin barrier dysfunction in atopic dermatitis

interactivity

The Cycle of Inflammation in Adult Asthma

5 min

Pulmonology

Explore the role of chronic type 2 inflammation in the cycle of exacerbations and worsening lung function in asthma patients

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: FranceChange country/region